Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACONGet Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 19,700 shares, a decline of 50.8% from the August 15th total of 40,000 shares. Based on an average trading volume of 544,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aclarion stock. Captrust Financial Advisors bought a new stake in Aclarion, Inc. (NASDAQ:ACONFree Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 78,400 shares of the company’s stock, valued at approximately $61,000. Captrust Financial Advisors owned approximately 1.00% of Aclarion at the end of the most recent quarter. Institutional investors and hedge funds own 7.52% of the company’s stock.

Aclarion Price Performance

Aclarion stock opened at $0.40 on Thursday. The company’s 50 day simple moving average is $0.55 and its 200-day simple moving average is $0.72. Aclarion has a 1 year low of $0.36 and a 1 year high of $2.37.

Aclarion (NASDAQ:ACONGet Free Report) last announced its earnings results on Friday, August 25th. The company reported ($0.18) earnings per share for the quarter. Aclarion had a negative return on equity of 332.11% and a negative net margin of 6,241.79%. The business had revenue of $0.02 million for the quarter.

Aclarion Company Profile

(Get Free Report)

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.

Further Reading

Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with's FREE daily email newsletter.